Download the Protocol

KPV

KPV is a natural compound found in the body that helps calm inflammation and promote healing. It has been studied for soothing the gut and skin, protecting tissue, and reducing redness or irritation. It may support recovery in research models involving inflammation but has not been fully tested in humans.

Description

• KPV is a natural tripeptide fragment of the hormone alpha-melanocyte-stimulating hormone (α-MSH).
• Composed of lysine, proline, and valine, it retains the anti-inflammatory and immunomodulatory activity of α-MSH.
• Studied for its role in reducing local inflammation, promoting epithelial healing, and protecting barrier tissues.

How It Works

• Binds to melanocortin receptors (mainly MC1R and MC3R) on immune and epithelial cells.
• Suppresses pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6.
• Enhances epithelial cell migration and repair, supporting mucosal and skin regeneration.

Documented Effects

• Reduces inflammation in models of colitis, dermatitis, and wound healing.
• Protects intestinal barrier integrity and decreases oxidative stress.
• Demonstrates antimicrobial and immune-regulatory effects in topical and systemic studies.
• Promotes faster recovery of damaged mucosa and skin in experimental animals.

Theoretical Effects

• Potential support for inflammatory bowel disease, eczema, and other inflammatory skin conditions.
• May complement peptides like BPC-157 for mucosal healing research.
• No large-scale human clinical data confirming safety or efficacy.

Pharmacokinetics

• Half-life: Approximately 30–60 minutes after subcutaneous administration.
• Time to peak concentration: About 15–30 minutes post-injection.
• Steady-state: Not typically achieved; activity is transient and pulse-based.

Duration of Effects

• Local anti-inflammatory effects may last 4–6 hours after dosing.
• Barrier and epithelial healing activity may persist for 12–24 hours.
• Effects diminish rapidly upon discontinuation, returning to baseline within a day.

Reconstitution

• Use only bacteriostatic water for reconstitution.
• Example vial: 10 mg of KPV peptide
• Choose reconstitution volume based on dosing convenience:
  • 1 mL water → 10 mg/mL → 1 mg per 10 units
  • 2 mL water → 5 mg/mL → 500 mcg per 10 units
• Swirl gently to dissolve—avoid vigorous shaking.
• Refrigerate reconstituted solution (2–8 °C). Use within ~30 days for best stability.

Injectable Dosage Overview (Research Reference)

Typical Starting Dose

• Research range: ~200–500 mcg subcutaneous (SC) once daily.
• Conservative entry point: start at 200 mcg per day to assess tolerance.

Common Research Range

• Typical studies: 250–1000 mcg SC daily for anti-inflammatory or gut-healing purposes.
• Occasionally combined with BPC-157 in preclinical mucosal repair protocols.

Maximum Daily Dose

• No defined upper limit; most experiments remain below 1 mg/day SC.
• Higher doses lack data and potential benefit remains unverified.

Standard Cycle Length

• Short protocols: 2–4 weeks continuous exposure.
• Longer observation: 4–6 weeks on → 2–4 weeks off if repeating.

Clinical Notes

• Administered subcutaneously near affected area or systemically depending on research goal.
• Stable for about 30 days when refrigerated (2–8°C). Protect from light and heat. Avoid freezing.
• Can be paired experimentally with BPC-157 or TB-500 for tissue recovery models.
• Do not combine peptides in the same syringe or vial unless confirmed stable together.

Safety Notes

• Evidence limited to preclinical and small pilot studies.
• Maintain sterile handling and confirm peptide source purity.
• Do not mix in the same vial with unrelated peptides.
• For laboratory and research use only; not approved for human therapeutic administration.